BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease
The agreement adds a second potential Fabry treatment, with $70 million upfront and up to $405 million in additional milestone payments.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioMarin Pharmaceutical (BMRN) entered an exclusive license agreement with GC Biopharma and Hanmi Pharm for investigational Fabry disease therapy HM15421/GC1134A.
The agreement grants rights worldwide excluding Korea, with a $70 million upfront payment, up to an additional $405 million in development and commercial milestone payments, and tiered royalties on net sales. The long-acting enzyme replacement therapy, administered under the skin, is in a Phase 1/2 trial. After that study, BioMarin will assume sole responsibility for subsequent clinical development, manufacturing and commercialization outside Korea; GC and Hanmi retain Korean commercialization rights. The candidate received FDA Orphan Drug Designation in 2024.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointExclusive rights outside Korea add HM15421/GC1134A to BioMarin's Fabry disease development portfolio.
- Minor pointFDA Orphan Drug Designation was granted to HM15421/GC1134A in 2024.
Negative
- Moderate point$70 million upfront payment is due under the license agreement.
- Minor point. Forward-looking: it has not happened yet and may not happen.Up to $405 million in additional payments depend on development and commercial milestones; tiered royalties apply to net sales.
- Minor point. Forward-looking: it has not happened yet and may not happen.Sole responsibility for subsequent development, manufacturing and commercialization outside Korea transfers to BioMarin after the ongoing Phase 1/2 study.
Key Figures
- Upfront payment
- $70 million
- License agreement
- Potential milestone payments
- Up to $405 million
- Development and commercial milestones
- Study phase
- Phase 1/2
- Investigational Fabry disease therapy
- Orphan Drug Designation
- 2024
- U.S. FDA designation
Key Terms
enzyme replacement therapy medical
alpha-galactosidase a medical
tiered royalties financial
orphan drug designation regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Agreement grants BioMarin worldwide rights (excluding
BioMarin will make an upfront payment of
HM15421/GC1134A is a human recombinant alpha-galactosidase A (a-Gal A) enzyme therapy currently being studied in a Phase 1/2 clinical trial in people living with Fabry disease and has the potential to be the first subcutaneous enzyme replacement therapy for Fabry disease.
"This agreement reflects our growing commitment to the Fabry community, building on the acquisition of Amicus earlier this year," said Alexander Hardy, President and Chief Executive Officer of BioMarin. "HM15421/GC1134A has the potential to offer a new way of treating Fabry disease, and we believe it could be an important option for patients. As we continue to add to our clinical portfolio, both through internal research and external programs, HM15421/GC1134A is an excellent fit and could allow us to reach a new generation of patients with Fabry beyond those with mutations amenable to treatment with GALAFOLD."
Under the terms of the agreement, BioMarin will make an upfront payment of
In preclinical studies, HM15421/GC1134A demonstrated differentiated efficacy across key measures, including renal function, vascular health and peripheral nervous system outcomes. The candidate received Orphan Drug Designation from the
About Fabry Disease
Fabry disease is a lysosomal storage disorder caused by inherited genetic changes in the GLA gene, which hampers activity of the enzyme alpha-galactosidase A (a-Gal A). Reduced a-Gal A activity leads to lysosomal accumulation of globotriaosylceramide (GL-3), which is believed to cause the various symptoms of Fabry disease, including pain, kidney failure and increased risk of heart attack and stroke. The symptoms can be severe, differ from person to person, and begin at an early age.
About HM15421/GC1134A
HM15421/GC1134A is an investigational, long-acting enzyme replacement therapy for Fabry disease, a rare, X-linked lysosomal storage disorder caused by deficient alpha-galactosidase A activity. HM15421/GC1134A is designed to extend half-life and improve stability relative to currently available enzyme replacement therapies, supporting subcutaneous dosing. HM15421/GC1134A is currently being evaluated in a Phase 1/2 clinical trial.
About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.
Forward-Looking Statements
This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including without limitation, statements about: the plans and expectations regarding the exclusive worldwide license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. to develop and commercialize HM15421/GC1134A for Fabry disease; expectations regarding HM15421/GC1134A, including commercial prospects, potential benefits of HM15421/GC1134A for patients with Fabry disease, and the potential to be the first subcutaneous treatment for Fabry disease; and prospects and timing of actions relating to preclinical and clinical studies and approvals. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others, results and timing of current and planned preclinical studies and clinical trials and the release of data from those trials; any potential adverse events observed in the continuing monitoring of the patients in the clinical trials; the content and timing of decisions by the U.S. Food and Drug Administration, the European Medicines Agency, the European Commission and other regulatory authorities; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as such factors may be updated by any subsequent reports. Investors are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.
BioMarin® is a registered trademark of BioMarin Pharmaceutical Inc.
|
Contacts: |
|
|
|
|
|
Investors |
Media |
|
Traci McCarty |
Erin Rau |
|
BioMarin Pharmaceutical Inc. |
BioMarin Pharmaceutical Inc. |
|
(415) 455-7558 |
(925) 683-9622 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-enters-into-exclusive-worldwide-license-agreement-with-gc-biopharma-and-hanmi-pharm-for-investigational-next-generation-enzyme-replacement-therapy-adding-a-second-potential-treatment-for-fabry-disease-302923678.html
SOURCE BioMarin Pharmaceutical Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the financial terms of BioMarin's HM15421/GC1134A license agreement?
BioMarin will pay $70 million upfront, with GC and Hanmi jointly eligible for up to an additional $405 million upon completion of certain development and commercial milestones, plus tiered royalties on net sales.
How could HM15421/GC1134A expand BioMarin's Fabry disease treatment options?
BioMarin believes HM15421/GC1134A could reach patients beyond those with mutations amenable to treatment with GALAFOLD. The agreement builds on its acquisition of Amicus earlier in 2026 and adds a second potential treatment for Fabry disease.